Home > Healthcare > Medical Devices > Diagnostic Devices > Cancer Diagnostics Market

Cancer Diagnostics Market Analysis

  • Report ID: GMI2406
  • Published Date: Jan 2023
  • Report Format: PDF

Cancer Diagnostics Market Analysis

Global Cancer Diagnostics Market Share, By Application

To understand key trends  
Download Free Sample
 

Cancer diagnostics market size from imaging applications is anticipated to record over 8.5% CAGR between 2023-2032. Cancer diagnostics are extensively used several imaging applications including mammography, ultrasound, MRI scan, radiology, PET scan, and SPECT. With an upsurge in cancer cases across developed and developing nations, the demand for faster and more efficient screening technologies has picked huge pace. Imaging also allows healthcare professionals to make an informed decision regarding the course of treatment. Furthermore, the emergence of groundbreaking developments, such as photon-counting CT scanners based on quantum technology, and dark-field imaging will showcase lucrative scope for the industry development.
 

Cancer Diagnostics Market Share (%), By End-Use, 2022

Segment

Market share (%), 2022

Hospitals

40.7%

Diagnostic Laboratories

35.9%

Diagnostic Imaging Centers

16.8%

Cancer Research Institutes

6.6%

Hospitals segment in the cancer diagnostics market was valued at more than USD 55 billion in 2022. The increasing focus on the advancement of healthcare infrastructure has encouraged the establishment of technologically equipped hospitals. The growing disease burden is further propelling the need for modern systems suitable for faster and more efficient biopsy procedures. Additionally, hospitals have a high preference among patients as they offer access to multi-specialty domains with superior diagnostic aid and healthcare professionals. With increasing medical tourism worldwide, multiple countries are investing heavily in healthcare facilities, further complementing the industry expansion.
 

In terms of revenue, the cancer diagnostics market share from non-Hodgkin lymphoma (NHL) is estimated to reach over USD 18.5 billion 2032. The rising prevalence of NHL will proliferate the adoption of cancer diagnostic technologies. According to the American Cancer Society, NHL is one of the most prevalent types of cancers in the U.S., responsible for 4% of all cancers. In 2022, NHL was estimated to affect more than 80,000 people, causing nearly 20,250 deaths. The growing geriatric population across the globe will represent a lucrative need for cancer diagnostics since individuals above the age of 65 years showcase a higher prevalence of NHL.
 

Moreover, a surge in melanoma cases is expected to further drive the demand for cancer diagnostics. Melanoma is most invasive type of skin cancer and can be life threatening, thus fueling the need for surgeries, medications, radiation and even chemotherapy. According to a study published in the JAMA Journal, by 2040, new melanoma cases across the globe are projected to increase by 50%, while melanoma-related mortality will witness a 68% surge.
 

Global Cancer Diagnostics Market Size, By Region

To understand key market trends  
Download Free Sample
 

Europe cancer diagnostics market size is slated to surpass USD 93.5 billion by 2032. Increasing healthcare expenditure will play a crucial role in the industry expansion. The region also records high awareness regarding early cancer diagnosis along with a solid footprint of companies specializing in cancer diagnostic tests. Furthermore, several EU agencies and health organizations are providing funding and new schemes to boost innovation in cancer diagnostics.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for cancer diagnostics was worth more than USD 136 billion in 2022 and is projected to exhibit over 9% CAGR from 2023-2032.

Non-Hodgkin lymphoma (NHL) is estimated to reach over USD 18.5 billion by 2032 due to increasing prevalence in the aging population.

Europe cancer diagnostics market size is slated to surpass USD 93.5 billion by 2032 owing to the presence of growing healthcare expenditure and supportive initiatives.

Abbott Laboratories, BioMerieux SA, Biocartis, Hologic Inc, Qiagen N.V, Myriad Genetics, Inc, and Sysmex Corporation are some key participants in the market.

Cancer Diagnostics Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 19
  • Tables & Figures: 274
  • Countries covered: 18
  • Pages: 300
 Download Free Sample